AZ's Imfinzi reduces the risk of death by 32% in non-progressing Phase III NSCLC trial

AstraZeneca plc (LSE:AZN; NYSE:AZN) said PD-L1 inhibitor Imfinzi durvalumab reduced the risk of death by 32% in the Phase III PACIFIC trial to treat locally advanced, unresectable non-small cell lung cancer (NSCLC) in 713 patients who have not progressed following standard platinum-based chemotherapy concurrent with radiation. Data were presented at the World Conference on Lung Cancer in Toronto and published in the New England Journal of Medicine.

In the double-blind, international trial, median overall survival (OS) was not reached in the Imfinzi arm vs. a median OS of 28.7 months in the placebo arm (HR=0.68, 99.73% CI: 0.47, 0.997, p=0.0025). Imfinzi led to an updated median progression-free survival (PFS) of 17.2 months vs. 5.6 months for placebo (HR=0.51, 95% CI: 0.41, 0.63)...